Ticker > Company >

Trident Texofab share price

Trident Texofab Ltd.

BSE: 540726 SECTOR: Textile  20k   24   3

161.90
0 0
BSE: 20 Dec 04:01 PM

Price Summary

Today's High

₹ 161.9

Today's Low

₹ 161.9

52 Week High

₹ 161.9

52 Week Low

₹ 36.15

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

163.03 Cr.

Enterprise Value

199.84 Cr.

No. of Shares

1.01 Cr.

P/E

75.65

P/B

9.08

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  17.82

CASH

0.16 Cr.

DEBT

36.96 Cr.

Promoter Holding

57.79 %

EPS (TTM)

₹  2.14

Sales Growth

3.25%

ROE

6.88 %

ROCE

10.11%

Profit Growth

-51.32 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year3.25%
3 Year25.85%
5 Year2.74%

Profit Growth

1 Year-51.32%
3 Year45.15%
5 Year-3.26%

ROE%

1 Year6.88%
3 Year10.19%
5 Year8.38%

ROCE %

1 Year10.11%
3 Year10.71%
5 Year11.24%

Debt/Equity

2.2752

Price to Cash Flow

60.08

Interest Cover Ratio

1.2895

CFO/PAT (5 Yr. Avg.)

1.63873292326882

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 57.79 0.00
Jun 2024 59.11 0.00
Mar 2024 61.74 0.00
Dec 2023 61.33 0.00
Sep 2023 61.33 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 45.1538662115741% for the Past 3 years.
  • The company has shown a good revenue growth of 25.8505424025442% for the Past 3 years.
  • The company has a good cash flow management; CFO/PAT stands at 1.63873292326882.
  • The company has a high promoter holding of 57.79%.

 Limitations

  • Tax rate is low at 7.6061.
  • The company is trading at a high PE of 75.65.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 23.2 23.01 30.17 25.71 26.45
Total Expenditure 21.94 21.11 29.15 24.19 26.72
Operating Profit 1.26 1.9 1.02 1.52 -0.28
Other Income 1.03 0.11 0.05 0.86 2.77
Interest 1.07 0.93 1.14 1.05 1.13
Depreciation 0.41 0.41 0.42 0.41 0.41
Exceptional Items 0 0 0.34 0 0
Profit Before Tax 0.81 0.67 -0.14 0.92 0.95
Tax 0.06 0.11 -0.04 0.22 -0.06
Profit After Tax 0.75 0.56 -0.1 0.7 1
Adjusted EPS (Rs) 0.75 0.55 -0.1 0.69 1

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 90.96 49.91 84.29 96.36 99.48
Total Expenditure 86.14 47.03 79.5 90.05 93.33
Operating Profit 4.83 2.88 4.79 6.31 6.16
Other Income 0.42 1.85 0.74 1.9 0.39
Interest 2.71 2.85 2.83 3.71 4.04
Depreciation 1.01 1.02 1.47 1.64 1.65
Exceptional Items 0 0.05 0.04 -0.13 0.31
Profit Before Tax 1.53 0.9 1.27 2.73 1.17
Tax 0.63 0.55 0.29 0.51 0.09
Net Profit 0.9 0.35 0.98 2.22 1.08
Adjusted EPS (Rs.) 0.94 0.35 0.98 2.2 1.07

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 4.2 10.07 10.07 10.07 10.07
Total Reserves 7.43 1.91 2.89 5.11 6.19
Borrowings 10.55 19.19 20.27 18.58 17.74
Other N/C liabilities 4.25 6.38 7.51 6.31 5.62
Current liabilities 29.25 30.23 30.25 37.23 42.28
Total Liabilities 55.68 67.77 70.99 77.31 81.9
Assets
Net Block 12.48 14.21 21.71 23.33 21.73
Capital WIP 0.3 8.89 3.62 0 0
Intangible WIP 0 0 0 0 0
Investments 1.12 2.48 2.06 3.64 3.74
Loans & Advances 0.41 0.59 0.23 0.22 0.22
Other N/C Assets 1.43 1.6 3.34 3.43 4.1
Current Assets 39.94 40 40.03 46.69 52.1
Total Assets 55.68 67.77 70.99 77.31 81.9
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1.53 0.9 1.27 2.73 1.17
Adjustment 3.68 2.92 4.64 4.33 5.79
Changes in Assets & Liabilities -7.56 -1.63 -4.52 -1.07 -4.13
Tax Paid -0.5 -0.23 0 -0.13 -0.12
Operating Cash Flow -2.85 1.96 1.39 5.85 2.71
Investing Cash Flow -2.41 -10.19 -4.38 0.37 -0.57
Financing Cash Flow 4.95 8.19 2.99 -6.2 -2.05
Net Cash Flow -0.31 -0.05 0 0.02 0.09

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 61.33 61.33 61.74 59.11 57.79
anjanaben jigishkumar des... 0.48 0.48 0.48 0.48 0.48
chetan chandrakant jariwa... 15.07 15.07 15.07 15.07 15.07
hardik jigishkumar desai 34.96 34.96 34.96 32.32 31.01
hardik jigishkumar desai,... 9.14 9.14 9.34 9.34 9.34
kailashben chandrakant ja... 0.21 0.21 0.21 0.21 0.21
maniya hardik desai 1.17 1.17 1.17 1.17 1.17
rupaben chetanbhai jariwa... 0.19 0.19 0.19 0.19 0.19
trident lifeline limited 0.10 0.10 0.32 0.32 0.32
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 38.67 38.67 38.26 40.89 42.21
amit bhupendrabhai halvaw... 1.00 - 1.00 1.00 1.00
dhavl shah 1.43 - 1.43 1.43 1.43
narshibhai meghjibhai mer... 1.04 - 1.04 1.04 1.04
national stock exchange o... - - - - 1.31
shravan h patel 1.82 - 1.82 - 1.82
il and fs securities serv... 1.31 1.31 1.31 1.31 -
sanket ramesh fuke - - - 1.25 -
shravan harikrishnabhai p... - - - 1.82 -

Ratings & Research Reports

Company Presentations

Company News

Trident Texofab - Quaterly Results 12 Oct, 3:56 PM Trident Texofab - Quaterly Results 12 Oct, 3:56 PM Trident Texofab - Quaterly Results 12 Oct, 3:56 PM Trident Texofab informs about newspaper publication 5 Sep, 4:47 PM Trident Texofab - Quaterly Results 18 Jul, 3:38 PM Trident Texofab - Quaterly Results 18 Jul, 3:38 PM Trident Texofab - Quaterly Results 18 Jul, 3:38 PM Trident Texofab - Quaterly Results 25 May, 3:10 PM Trident Texofab - Quaterly Results 25 May, 3:10 PM Trident Texofab - Quaterly Results 25 May, 3:10 PM Trident Texofab informs about closure of trading window 30 Mar, 3:28 PM Trident Texofab - Quaterly Results 14 Feb, 6:29 PM Trident Texofab - Quaterly Results 6 Nov, 6:16 PM Trident Texofab - Quaterly Results 6 Nov, 6:16 PM Trident Texofab - Quaterly Results 10 Aug, 6:32 PM Trident Texofab - Quaterly Results 24 Apr, 8:33 PM Trident Texofab - Quaterly Results 24 Apr, 8:33 PM Trident Texofab informs about outcome of board meeting 29 Mar, 2:38 PM Trident Texofab informs about disclosure 25 Mar, 3:32 PM Trident Texofab informs about disclosure 1 Mar, 4:54 PM Trident Texofab informs about disclosure 1 Feb, 5:18 PM Trident Texofab informs about press release 18 Jan, 4:28 PM Trident Texofab - Quaterly Results 16 Jan, 2:11 PM Trident Texofab - Quaterly Results 16 Jan, 2:11 PM Trident Texofab - Quaterly Results 16 Jan, 2:11 PM Trident Texofab informs about press release 7 Dec, 12:34 PM Trident Texofab informs about compliances-certificate 15 Oct, 3:50 PM Trident Texofab informs about board meeting proceedings 11 Oct, 5:04 PM Trident Texofa informs about outcome of board meeting 11 Oct, 5:02 PM Trident Texofab - Quaterly Results 11 Oct, 1:24 PM Trident Texofab - Quaterly Results 11 Oct, 1:24 PM Trident Texofab - Quaterly Results 11 Oct, 1:24 PM Trident Texofab to raise Rs 12 crore through NCDs 19 Sep, 10:30 AM Trident Texofab - Quaterly Results 12 Jul, 4:59 PM Trident Texofab - Quaterly Results 12 Jul, 4:59 PM Trident Texofab - Quaterly Results 12 Jul, 4:59 PM Trident Texofab informs about disclosure 6 Jun, 10:13 AM Trident Texofab - Quaterly Results 21 Apr, 5:54 PM Trident Texofab - Quaterly Results 21 Apr, 5:54 PM Trident Texofab - Quaterly Results 21 Apr, 5:54 PM Trident Texofab - Quaterly Results 19 Jan, 5:54 PM Trident Texofab - Quaterly Results 19 Jan, 5:54 PM Trident Texofab informs about disclosure 29 Dec, 4:50 PM Trident Texofab informs about disclosures 23 Dec, 5:02 PM Trident Texofab informs about disclosure 6 Dec, 5:19 PM Trident Texofab informs about disclosure 6 Dec, 5:01 PM Trident Texofab informs about investor presentation 27 Oct, 2:39 PM Trident Texofab informs about certificate 7 Oct, 3:51 PM Trident Texofab informs about disclosure 4 Oct, 1:21 PM Trident Texofab informs about proceedings of 13th AGM 21 Sep, 1:28 PM

Trident Texofab Stock Price Analysis and Quick Research Report. Is Trident Texofab an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Trident Texofab stock price today is Rs 161.9. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Trident Texofab . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Trident Texofab has a PE ratio of 75.6542056074766 which is high and comparatively overvalued .

  • Share Price: - The current share price of Trident Texofab is Rs 161.9. One can use valuation calculators of ticker to know if Trident Texofab share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Trident Texofab has ROA of 1.3566 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Trident Texofab has a Current ratio of 1.2323 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Trident Texofab has a ROE of 6.8776 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Trident Texofab has a Debt to Equity ratio of 2.2752 which means that the company has high proportion of debt in its capital.

  • Sales growth: - Trident Texofab has reported revenue growth of 3.246 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Trident Texofab for the current financial year is 6.18746444130376 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Trident Texofab is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Trident Texofab is Rs 2.14 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Trident Texofab in Ticker for free. Also, one can get the intrinsic value of Trident Texofab by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Trident Texofab
X